Healthcapital SA actively sources internationally for privately-held companies world wide that are creating new product opportunties and next generatioon technologies that address real unmet medical needs. We have a significant focus on biopharmaceutical companies with proprietary compounds or technologeis that have the potentail to become new therapies. We target preferentially high growth biotech businesses that have the potential to deliver return of 3 times or more of the principal investment in 5 years time frame .
We aim to balance the levels of risk and to focus on the timing of returns, with a considerable emphasis on investments with low risk and the potential for early returns. These investments will be matched with a portion of the portfolio consisting of innovative companies with a potential of very high returns. We typically aim to have the life cycle of invetment in a company, tthat is, from the time we make the first investment to the company's exit, in the range of 3 - 5 years.